Table 7Quantified minimal clinically important differences for total nasal symptom score

SourceMCIDScale
1. Distribution-based approach in 27 patients62, 720.520-12 interval
2. Responsiveness of visual analog scale to interval scale732.90-10 visual analog
3. Allergen-specific immunotherapy recommendation7530%aany
4. Technical Expert Panel input2-40-12 interval

MCID = minimal clinically important difference.

a

A 30 percent greater improvement compared to placebo in composite symptom/rescue medication use scores was proposed as minimally clinically meaningful.

From: Methods

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.